Mission Wealth Management LP Acquires New Holdings in Moderna, Inc. (NASDAQ:MRNA)

Mission Wealth Management LP bought a new position in Moderna, Inc. (NASDAQ:MRNA) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 2,063 shares of the company’s stock, valued at approximately $205,000.

A number of other large investors have also recently added to or reduced their stakes in the stock. Allworth Financial LP increased its position in Moderna by 6.5% in the 4th quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock worth $165,000 after buying an additional 101 shares during the period. TIAA Trust National Association grew its stake in shares of Moderna by 2.3% in the fourth quarter. TIAA Trust National Association now owns 4,491 shares of the company’s stock worth $447,000 after acquiring an additional 102 shares during the last quarter. Sound Income Strategies LLC increased its position in Moderna by 17.8% during the fourth quarter. Sound Income Strategies LLC now owns 762 shares of the company’s stock worth $76,000 after acquiring an additional 115 shares during the period. Bay Colony Advisory Group Inc d b a Bay Colony Advisors raised its stake in Moderna by 6.5% during the 4th quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 2,459 shares of the company’s stock valued at $245,000 after purchasing an additional 151 shares during the last quarter. Finally, Bristlecone Advisors LLC boosted its holdings in Moderna by 2.6% in the 4th quarter. Bristlecone Advisors LLC now owns 5,999 shares of the company’s stock valued at $597,000 after purchasing an additional 153 shares during the period. Institutional investors own 75.33% of the company’s stock.

Moderna Trading Down 0.5 %

Shares of MRNA stock opened at $125.00 on Friday. The company has a market capitalization of $47.86 billion, a P/E ratio of -7.98 and a beta of 1.57. Moderna, Inc. has a 12-month low of $62.55 and a 12-month high of $142.79. The company has a quick ratio of 3.36, a current ratio of 4.03 and a debt-to-equity ratio of 0.04. The firm has a 50-day moving average price of $105.05 and a 200 day moving average price of $94.42.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.59) by $0.52. The company had revenue of $167.00 million during the quarter, compared to analysts’ expectations of $93.26 million. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. Moderna’s quarterly revenue was down 91.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.19 earnings per share. Research analysts forecast that Moderna, Inc. will post -7.47 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on MRNA. HSBC restated a “reduce” rating and set a $86.00 price objective (up previously from $75.00) on shares of Moderna in a report on Monday, February 26th. Canaccord Genuity Group upped their price target on Moderna from $91.00 to $106.00 and gave the company a “hold” rating in a report on Friday. Royal Bank of Canada raised their price objective on Moderna from $125.00 to $135.00 and gave the stock an “outperform” rating in a research report on Friday. William Blair restated a “market perform” rating on shares of Moderna in a research report on Monday, April 1st. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research report on Thursday. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $129.55.

Insider Activity at Moderna

In other news, President Stephen Hoge sold 2,388 shares of the firm’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $225,833.16. Following the completion of the sale, the president now directly owns 1,515,898 shares in the company, valued at $143,358,473.86. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other Moderna news, insider Shannon Thyme Klinger sold 670 shares of the company’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $63,361.90. Following the transaction, the insider now owns 8,557 shares of the company’s stock, valued at approximately $809,235.49. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, President Stephen Hoge sold 2,388 shares of Moderna stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $225,833.16. Following the completion of the sale, the president now directly owns 1,515,898 shares of the company’s stock, valued at $143,358,473.86. The disclosure for this sale can be found here. Insiders sold 139,954 shares of company stock valued at $14,822,576 in the last three months. Corporate insiders own 15.70% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.